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INTRODUCTION 
 
In an era of severe donor organ shortage and growing waiting lists for renal transplantation there is an 
increased reliance on expanded criteria donors and organs donated after circulatory death (DCD). While DCD 
donor kidneys constitute a large potential donor pool, higher incidences of primary non-function and particularly 
delayed graft function (DGF) are regarded as major impediments.  
Notwithstanding the higher incidence of DGF in DCD compared to DBD grafts, large cohort studies 
from the United Kingdom and The Netherlands show equivalent survival for kidneys donated after brain death 
(DBD) and DCD grafts. 1-3 This observation suggests a differential impact of DGF on DBD and DCD graft 
survival.  
 The apparent differential impact of DGF on DBD and DCD graft survival is remarkable and yet 
unexplained. One possible explanation for this phenomenon is that the type of DGF in DBD grafts reflects more 
severe transplantation-related injury.  An alternative and mutually non-exclusive explanation is that the 
differential impact reflects differences in graft ‘resilience’ – i.e. the ability of the graft to cope with negative 
environmental changes4 – with DCD donor kidneys being more ‘resilient’ than DBD grafts. Tissue resilience is 
an established phenomenon in cancer biology, and negatively associates with patient prognosis.4 However, in the 
context of transplantation biology, resilience could be a beneficial factor potentially contributing to better 
transplantation outcomes. 
 Considering the emerging epidemiological evidence for a different impact of DGF on DBD and DCD 
graft survival and its clinical relevance, we have focused in this hypothesis generating study on this putative 
differential impact and also attempted to explore its biological basis.  
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METHODS 
 
Study population 
The impact of DGF (defined as the need for dialysis in the first postoperative week(s))on long-term 
graft survival was evaluated in 6,635 deceased donor kidney transplants performed between January 2000 and 
January 2018 in the Netherlands (Netherlands Organ Transplant Registry (NOTR)). Combined organ procedures, 
procedures in recipients younger than 12 years and uncontrolled circulatory death donor procedures were 
excluded. 
The impact of donor type on DGF phenotype and functional recovery dynamics was assessed for 287 
DBD and 312 DCD kidney transplants performed at the Leiden University Transplant Center between 2007 and 
2018. A more detailed description of the methods is given in the Supplemental Data.  
The clinical nomenclature and different phases included in this paper are illustrated in Figure 1.  
 
Histology and gene expression 
Pre-reperfusion tissue biopsy samples from 80 donor kidneys were randomly selected based on donor 
type and the presence or absence of DGF (n=20 per group, Supplemental Table 1). Immunohistochemical 
staining was performed for BCL2, IGF-1R, p53, PCNA, phospho-EGFR, phospho-MAPK14, phospho-mTOR, 
PPARγ. Details of the antibodies and procedures are summarized in the Supplemental Data and Supplemental 
Table 2. 
Gene expression profiling of pre-reperfusion renal biopsies and Ingenuity®Pathway Analysis (IPA®, 
QIAGEN, USA) was used to identify differentially regulated pathways in 23 DBD and 16 DCD grafts 
(Supplemental Table 3).  
All renal biopsies used in this study were collected after static cold storage, immediately prior to 
reperfusion. Further details of the analyses are provided in the Supplemental Data. 
 
Statistical analysis 
STATA/SE version 12.0 (StataCorp, Texas, USA) and IBM SPSS Statistics 23.0 (Amsterdam, The 
Netherlands) were used for statistical analysis. Comparisons between groups were analyzed using standard 
statistical methods. Cox proportional hazards models, adjusted for donor/recipient age and sex, were used to 
evaluate differences in impact of DGF on 10-year graft survival. Univariate analysis was followed by 
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multivariate regression analysis to identify factors associated with DGF. A detailed description of the statistical 
analysis is given in the Supplemental Data. 
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RESULTS 
 
Epidemiological evaluation 
 
Putative differential impacts of DGF on DBD and DCD graft survival were evaluated in 6,635 kidney 
transplants (including 43.6% DCD procedures) that were performed between 2000 and 2018 in The Netherlands 
(Supplemental Table 4). The registry data confirmed a higher incidence of DGF in DCD grafts (DCD: 42.2% vs. 
DBD: 17.8%; p<0.001) but also showed differential impact of DGF on long-term graft survival per donor type. 
In fact, while DGF severely impacted 10-year graft survival in DBD donor kidneys [adjusted DGF-associated 
hazard ratio (aHR) for graft loss: 1.67 (95%CI 1.35-2.08); p<0.001], no impact on survival was observed for 
DGF in DCD donor kidneys [aHR for graft loss 1.08 (95%CI 0.82-1.39); p=0.63]. The interaction test confirmed 
the differential impact of DGF on DBD and DCD long-term graft survival (p for interaction <0.001). 
 
The differential impact of DGF on long-term graft survival may relate to a greater threshold to develop 
DGF in DBD grafts (i.e. that development of DGF in DBD grafts requires a more severe insult). This hypothesis 
was tested by using a qualitative and quantitative evaluation of risk factors associated with DGF. An inventory 
of risk factors associated with occurrence of DGF (multivariate analyses) revealed clearly qualitative differences 
between the two donor types. The first warm ischemic period, a discriminant factor of DCD grafts, was 
positively associated with DGF in these grafts. Both donor types shared cold ischemic period as a risk factor for 
developing DGF. Donor age was a significant risk factor for DBD grafts, but an association with DGF in DCD 
grafts did not reach statistical significance (p = 0.11). The last serum creatinine value in the donor, human 
leukocyte antigen (HLA)-DR mismatch, and graft anastomosis time exclusively associated with DGF in DBD 
grafts but not in DCD grafts (Supplemental Table 5). 
Quantitative analysis showed that DGF in recipients of DBD grafts was associated with a slightly 
unfavorable donor and procedural profile as reflected by the 2-year difference in donor age, higher donor serum 
creatinine concentrations, and 8% and 12% longer cold ischemic and graft anastomosis times (Table 1a). 
However, this less favorable risk profile did not result in a more severe DGF phenotype in DBD grafts. On the 
contrary, recipients of DCD grafts with DGF required longer dialysis, and had profoundly inferior renal function 
(eGFR) in the first week following the last dialysis (p<0.001) (Table 1b). 
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The above results did not point to a more profound DGF phenotype as underlying cause of the negative 
impact of DGF on long-term graft survival in DBD grafts. Alternatively, the differing impact may reflect 
differential resilience between the two donor types, with DCD grafts being more resilient than DBD grafts. This 
concept is supported by the superior functional (eGFR) recovery dynamics in DCD grafts (Figure 2). 
 
Histology and gene expression 
  
To explore the presence of resilient enhancing factors, we included several molecular upstream 
regulators associated with resilience in the context of tumor biology (e.g. p53, phospho-EGFR, IGF-1R, 
phospho-mTOR, phospho-MAPK14, PCNA, BCL2 and PPARγ).5-11 The immunohistochemical analysis 
demonstrated expression of the aforementioned resilience factors in pre-reperfusion kidney biopsies, indicating 
that aspects of the molecular mechanisms associated with tissue resilience are present in both donor types 
(Supplemental Figures 1 and 2).  
 
With the aim of evaluating putative differential activation of molecular pathways associated with 
resilience in DBD and DCD grafts, an unbiased pathway analysis was performed on the gene expression profiles 
in pre-reperfusion kidney biopsies from DBD and DCD donors. There were no differences in baseline 
characteristics between DBD and DCD donors (Supplemental Table 3). Using DBD grafts as the comparator, six 
differentially activated (p < 0.05) upstream regulatory pathways, and 13 differentially inhibited regulatory 
pathways were identified in DCD grafts (Figure 3A). All upregulated pathways belonged to a family of factors 
responsible for renal development, cell fate, organogenesis, and stem cell maintenance. Pathways inhibited in 
DCD grafts included the p53 pathway, a cluster of pro-inflammatory factors (IL6, TNFα, RANKL (TNFSF11), 
CEBPβ, TICAM1) (Figure 3). Functionally, the strongest influence was found by pathways associated with 
cardio-vascular diseases (p-value range 2.5 10-10 - 2.2 10-3), in particular a gene cluster mapped by IPA as 
“advanced stage peripheral artery disease” (p-value 2.5 10-10). This cluster is dominated by upregulation of heat 
shock proteins (Supplemental Figure 3). 
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DISCUSSION   
 
While a high incidence of DGF after DCD kidney transplantation is considered a major obstacle 
towards a more liberal use of these grafts, recent epidemiological observations suggest that this concern might be 
unjustified. This integrative epidemiological and molecular analysis has clearly shown a differential impact of 
DGF on DBD and DCD graft survival, with no impact of DGF on DCD graft survival. This finding may reflect a 
more favorable baseline molecular resilience signature in DCD donor kidneys. 
 
 Transplants using DCD donor kidneys are associated with a 2 to 3-fold increase in incidence of 
DGF.2,3,12 DGF is an established risk factor for premature graft loss, and as such the higher incidence of DGF 
with DCD grafts is considered a relative contra-indication for the use of DCD grafts by some transplant centers. 
This notion has recently been challenged by cohort studies showing equivalent graft survival for DBD and DCD 
grafts despite the difference in incidence of DGF, an observation that implies a differential impact of DGF on 
DBD and DCD graft survival. In this context it should be noted that the conclusions regarding the negative 
association between DGF and long-term outcomes are mainly based on studies from an era with an almost 
exclusive use of DBD grafts.13-17 Moreover, it cannot be excluded that conclusions for DCD grafts are 
confounded by factors that relate to both DGF and graft survival. 
 
The differential impact of DGF on graft survival was confirmed by the outcome data for almost 6,700 
deceased donor kidney transplantations performed in The Netherlands, a country with a longstanding liberal 
tradition towards the use of DCD grafts (currently 50% of all deceased kidney transplantation procedures). 
While regression analysis confirmed the impact of DGF on long-term graft survival in DBD grafts, DGF did not 
affect graft survival in DCD grafts.  
  
 In an effort to understand the different impact of DGF on graft survival we first tested in this study 
whether the apparent impact on DBD grafts reflects the presence of a more severe DGF phenotype. This 
hypothesis was not supported by the clinical data. On the contrary, transplants with DCD grafts were hallmarked 
by a more severe graft injury as indicated by profoundly impaired post-transplant renal function (eGFR), and in 
case of DGF, a prolonged need for post-transplant dialysis. Irrespective of this, DCD grafts demonstrated an 
adequate functional recovery within weeks after transplantation, resulting in a renal function fully comparable to 
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DBD grafts. The impact of DGF on ultimate eGFR was similar for DBD and DCD grafts. Thus, our clinical data 
do not support a more severe DGF phenotype as underlying cause of the negative impact of DGF in DBD grafts. 
In this light, we explored possible differences in graft resilience as an alternative explanation for the contrasting 
impact of DGF in DBD and DCD grafts.  
 
 Biologically, resilience is the ability of an organism to recover to normal functioning after 
perturbation.18 In the context of ageing, resilience is the ability to cope with stress and re-establish homeostasis.19 
Tissue resilience is an established phenomenon in tumor biology, and a known negative prognostic factor.4 In the 
context of organ transplantation, superior resilience would obviously be beneficial in terms of graft recovery and 
survival. 
 
We applied gene expression profiling followed by pathway analysis to map putative molecular 
differences in organ resilience between DBD and DCD grafts. Pathways relatively enriched (n=6) in DCD grafts 
were all part of established resilience networks. Five upregulated pathways in DCD grafts (RET, Alpha catenin, 
GMNN, SOX1 and SOX3) were associated with renal development and cell proliferation, and partly associate 
with the Wnt/β-catenin signaling pathways;20-24 a pivotal pathway in kidney development, repair and 
regeneration.25-30 The sixth upregulated pathway was the BRCA1 tumor suppressor pathway. BRCA1 is a key 
player in cellular repair through its role in DNA repair and cell cycle checkpoint activation. This pathway was 
recently shown to be cardioprotective after myocardial infarction.31  In contrast to the BRCA-1 tumor suppressor 
pathway, we observed down-regulation of the p53 network. While this downregulation is considered a negative 
aspect in tumor biology, it has been pointed out that downregulation of p53 is part of the normal, physiological 
regenerative response, and as such, is part of an activated resilience network.32   
 
Downregulated pathways in DCD grafts were dominated by pro-inflammatory signaling cascades (i.e. 
IL6, TNFα, RANKL (TNFSF11), CEBPβ, TICAM1). This downregulation could be a consequence of an 
activated resilience network in DCD grafts. Other explanations included passive enrichment, reflecting 
differences in leucocyte influx (and thus genes associated with leucocytes) in DBD grafts,33 as well as 
upregulation of parenchymal inflammation in response to brain death in DBD grafts.34 It is unclear to what 
extent the relative downregulation of inflammatory responses in DCD grafts contributes to the absent impact of 
DGF in these grafts. Although inflammation is often seen as a “negative” factor, experimental data suggests that 
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brain death-associated immune activation may not accelerate ischemia reperfusion injury,35 whereas other 
studies actually indicate aggravation of experimental ischemia reperfusion injury following interference with IL-
6 or IL-9 signaling.33,36  
Another observation is the downregulation of the BDNF signaling route in DCD grafts. Strong 
associations exist between BDNF and the kidney injury molecule (KIM-1), and BDNF has been recently 
proposed as a biomarker for glomerular injury.37 As such, the relative downregulation of BDNF in DCD grafts 
might indicate that the glomerular injury is less in DCD than in DBD grafts.   
On the functional level, the most influential transcriptomic signals were related to cardio-vascular 
diseases, in particular “advanced stage peripheral artery disease”. This cluster is mainly comprised of members 
of heat shock protein superfamily. Induction of heat shock proteins following ischemia has been well 
documented. In the context of brain ischemia this was correlated with the regions that ultimately survived the 
injury,38 suggesting that this superfamily is part of a resilience response. 
 
Since all renal biopsies in this study were from grafts that were maintained on static cold storage (hence 
a state of absent transcriptional activity), the clear differences in gene expression profiles probably reflect donor 
specific aspects such as brain death.39 An alternative, and non-exclusive explanation, is that the activation of 
resilience pathways in DCD grafts is caused by a process of ischemic preconditioning that may occur during the 
agonal phase and first warm ischemic period prior to donor nephrectomy in DCD donors. Ischemic 
preconditioning, that generally refers to a preceding state of ischemia that is followed by reperfusion, is an 
established phenomenon in experimental studies.40-42 Yet, studies so far do not indicate a benefit of ischemic 
preconditioning for clinical kidney injury.43 It might be speculated that the ischemia applied in clinical studies is 
insufficient to induce activation of resilience pathways, and that more profound and localized triggers which 
occur during the agonal phase and first warm ischemic period in DCD donors are required.  
 
Our study has several limitations. It is in part based on registry data including the standard flaws of a 
registry with some data missing and a lack of predefined variables, leading to more heterogeneity in data 
registration. Outcomes are prone to confounding by indication with some clinicians being more critical than 
others when accepting or declining DCD grafts for transplantation. Also, exploration of molecular mechanisms 
is based on observational data. A more detailed experimental exploration and validation of the observed 
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differences is compromised by the profound species differences with regard to acute injury, ischemia 
reperfusion, and resilience.44,45 
 
In conclusion, results in this clinically relevant study show that DGF has no obvious impact on long-
term graft survival in DCD grafts. As such, the high incidence of DGF in DCD grafts should not be regarded a 
relative contraindication or impediment towards the use of these donor kidneys. The molecular evaluation 
performed suggests that the different impact of DGF in DBD and DCD grafts relates to donor type-specific 
regulation of resilience and pro-inflammatory pathways benefitting the DCD graft and its outcomes. 
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FIGURE LEGENDS 
 
Figure 1. The clinical nomenclature and different phases included in this paper. 
 
Figure 2. Functional renal recovery (eGFR) after kidney transplantation. 
 
Figure 3. Differentially regulated upstream regulators in DBD and DCD donor kidneys based on 
Ingenuity Pathway Analysis (DBD is reference). 
BDNF (Brain-derived neurotrophic factor); BRCA1 (Breast cancer-associated gene 1); Bvht (Braveheart); CEBPB 
(CCAAT/Enhancer Binding Protein-β); EZH2 (Enhancer of zeste homolog 2); GMNN (Geminin); IL6 
(Interleukin-6); PGR (Progesteron Receptor); RET (Rearranged during transfection); RETNLB (Resistin-like 
molecule β); SLC13A1 (Solute carrier family 13 member 1); SMAD4 (Sma (Caenorhabditis elegans) Mothers 
Against Decapentaplegia homologue 4); SOX1 (Sex determining region Y-box protein 1); SOX3 (Sex determining 
region Y-box protein 3); TICAM1 (Toll Like Receptor Adaptor Molecule 1); TNFα (Tumor Necrosis Factor α); 
TNFSF11 (Tumor Necrosis Factor ligand Superfamily member 11); TP53 (Tumor Protein p53).  
 
Supplemental Figure 1. Immunohistochemical scoring of pre-reperfusion kidney biopsies. Bars represent 
mean ± standard deviation. 
Expression of BCL2 (Kruskal-Wallis test p = 0.653), IGF-1R (p = 0.340), p53 (p = 0.268), PCNA (p = 0.846), 
phospho-MAPK14 (p = 0.510), phospho-mTOR (0.554), PPARγ (p = 0.350) did not differ between groups. 
Expression of phospho-EGFR was lower in DCD grafts without DGF (p = 0.002).  
 
Supplemental Figure 2. Immunohistochemical staining of pre-reperfusion kidney biopsies for factors 
associated with tumor resilience. Bars represent 100µm. 
A = BCL-2; B = IGF-1R; C = p53; D = PCNA; E = phospho-EGFR; F = phospho-MAPK14; G = phospho-
mTOR; H = PPARγ.  
 
Supplemental Figure 3. Illustration of Ingenuity Pathway Analysis (IPA). Strong influences were found on 
pathways collectively labelled by IPA as “cardio-vascular diseases”. The network annotated as “advanced stage 
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peripheral artery disease” constitutes the most differentially upregulated network (p-value <0.001). This network 
is dominated by members of the heat shock protein family.   
 
Table 1a. Comparison of risk factors associated with DGF in DBD and DCD graft recipients.  
 DBD DGF + 
n = 667 
DCD DGF + 
n = 1219 
p-value 
Donor age (years) 52.1 (14.4) 50.2 (14.5) 0.006 
Donor last creatinine (µmol/L) 77.0 [60.0 - 100.0] 68.0 [54.0 - 83.5] < 0.001 
Mismatch 
HLA-DR   0 
                   1 
                   2 
 
243 (36.5%) 
360 (54.1%) 
62 (9.3%) 
 
362 (29.9%) 
752 (62.0%) 
98 (8.1%) 
0.004 
Cold ischemic period (hours) 18.4 [14.4 - 23.0] 17.0 [13.1 - 21.0] < 0.001 
Graft anastomosis time (min.)  35.0 [26.0 – 42.0] 31.0 [25.0 – 40.0] < 0.001 
Data are presented as mean ± standard deviation (SD) or as number (%) or as median [25 and 75 IQR]. 
 
 
 
 
Table 1b. DGF phenotype in DBD and DCD graft recipients.  
 DBD DGF + 
n = 80 
DCD DGF + 
n = 179 
p-value 
Duration of dialysis (days) 7.5 [5.0 - 12.0] 9.0 [6.0 - 13.8] 0.039 
Number of dialysis 3.5 [3.0 - 5.8] 4.0 [3.0 - 6.0] 0.462 
First autonomous eGFR 20.3 [14.4 - 35.7] 13.4 [ 9.3 - 22.8] < 0.001 
Data are presented as median [25 and 75 IQR]. 
 
